Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- GALT
- Price
- 3.53
- Stock movement up
- +0.36 (11.36%)
- Company name
- Galectin Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 227.59M
- Ent value
- 354.23M
- Price/Sales
- 6321.92
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.49%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 24.30%
- 1 year return (CAGR)
- 184.68%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GALT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6321.92 |
| Price to Book | - |
| EV to Sales | 9839.78 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.47M |
| EPS (TTM) | -0.58 |
| FCF per share (TTM) | -0.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 36.00K |
| Gross profit (TTM) | -22.00K |
| Operating income (TTM) | -29.15M |
| Net income (TTM) | -37.30M |
| EPS (TTM) | -0.58 |
| EPS (1y forward) | -0.41 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -61.11% |
| Operating margin (TTM) | -80966.67% |
| Profit margin (TTM) | -103619.44% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.53M |
| Net receivables | 0.00 |
| Total current assets | 12.73M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 12.87M |
| Accounts payable | 5.39M |
| Short/Current long term debt | 122.31M |
| Total current liabilities | 136.44M |
| Total liabilities | 138.17M |
| Shareholder's equity | -125.30M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -30.62M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -30.62M |
| Dividends paid (TTM) | 149.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -289.96% |
| Return on Invested Capital | 1247.17% |
| Cash Return on Invested Capital | 1023.87% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.17 |
| Daily high | 3.56 |
| Daily low | 3.14 |
| Daily Volume | 285K |
| All-time high | 36.84 |
| 1y analyst estimate | 11.00 |
| Beta | 0.96 |
| EPS (TTM) | -0.58 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Mar 2026 |
Downside potential
Loading...
Downside potential data
| GALT | S&P500 | |
| Current price drop from All-time high | -90.42% | -0.89% |
| Highest price drop | -97.72% | -19.00% |
| Date of highest drop | 24 Dec 2024 | 8 Apr 2025 |
| Avg drop from high | -92.12% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 321 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
227.59M
Marketcap category
Small-cap
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Employees
15
Investor relations
-
SEC filings
CEO
Harold H. Shlevin
Country
USA
City
Norcross
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page